RU2019110848A - Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств - Google Patents

Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств Download PDF

Info

Publication number
RU2019110848A
RU2019110848A RU2019110848A RU2019110848A RU2019110848A RU 2019110848 A RU2019110848 A RU 2019110848A RU 2019110848 A RU2019110848 A RU 2019110848A RU 2019110848 A RU2019110848 A RU 2019110848A RU 2019110848 A RU2019110848 A RU 2019110848A
Authority
RU
Russia
Prior art keywords
composition
amino acid
acid sequence
seq
molecule
Prior art date
Application number
RU2019110848A
Other languages
English (en)
Other versions
RU2019110848A3 (ru
Inventor
Ашутош Чилкоти
Джайанта Бхаттачария
Original Assignee
Дьюк Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дьюк Юниверсити filed Critical Дьюк Юниверсити
Publication of RU2019110848A publication Critical patent/RU2019110848A/ru
Publication of RU2019110848A3 publication Critical patent/RU2019110848A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (31)

1. Композиция, содержащая агрегат из самособираемых полипептидов, где самособираемый полипептид содержит:
(a) первую аминокислотную последовательность (X1GVPG)x (SEQ ID NO:1), где X1 представляет собой аминокислоту и x составляет от 20 до 240;
(b) вторую аминокислотную последовательность (X2Gm)y (SEQ ID NO:2), где X2 представляет собой Y, F или W, m составляет от 0 до 3, и y составляет от 1 до 50;
(c) третью аминокислотную последовательность (CGG)z (SEQ ID NO:3), где z больше чем 1; и
(d) по меньшей мере, одна молекула присоединена к третьей аминокислотной последовательности через цистеиновую группу, где молекула имеет коэффициент распределения октанол-вода (logD), менее чем или равный 1,5 при pH 7,4.
2. Композиция по п. 1, где молекула представляет собой химиотерапевтическое или визуализирующее средство.
3. Композиция по п. 1, где молекула представляет собой гемцитабин.
4. Композиция по п. 1, где приблизительно от 2 до приблизительно 15 молекул присоединены к третьей аминокислотной последовательности.
5. Композиция по п. 1, где молекула присоединена к третьей аминокислотной последовательности через тиоловую группу.
6. Композиция по п. 1, где первая аминокислотная последовательность представляет собой (X1GVPG)m (SEQ ID NO:11), и где m составляет от 120 до 200.
7. Композиция по п. 1, где вторая аминокислотная последовательность представляет собой (X2G)n (SEQ ID NO:4), и где n составляет от 4 до 8.
8. Композиция по п. 1, где третья аминокислотная последовательность представляет собой (CGG)p (SEQ ID NO:5), и где p составляет от 4 до 12.
9. Композиция по п. 1, где X1 представляет собой A.
10. Композиция по п. 1, где X2 представляет собой Y.
11. Композиция по п. 1, где первая аминокислотная последовательность представляет собой (AGVPG)160 (SEQ ID NO:6).
12. Композиция по п. 1, где вторая аминокислотная последовательность представляет собой (YG)6 (SEQ ID NO:7).
13. Композиция по п. 1, где третья аминокислотная последовательность представляет собой (CGG)8 (SEQ ID NO:8).
14. Композиция по п. 1, где каждый самособираемый полипептид отдельно имеет молекулярную массу приблизительно от 20 кДа до приблизительно 300 кДа.
15. Композиция по п. 1, где агрегат из самособираемых полипептидов представляет собой наночастицу.
16. Композиция по п. 15, где молекула расположена в ядре наночастицы.
17. Композиция по п. 15, где наночастица имеет средний гидродинамический радиус приблизительно от 20 нм до приблизительно 200 нм.
18. Композиция по п. 15, где наночастица является стержнеобразной или сферической.
19. Композиция по п. 15, где наночастица содержит приблизительно от 50 до приблизительно 1000 самособираемых полипептидов на частицу.
20. Композиция по п. 1, дополнительно включающая фармацевтически приемлемый носитель.
21. Способ уничтожения множества злокачественных клеток, включающий контакт множества злокачественных клеток с композицией по п. 1.
22. Способ по п. 21, где множество злокачественных клеток присутствует у человека или собаки.
23. Способ по п. 21, где множество злокачественных клеток находится in vitro.
24. Способ лечения заболевания или нарушения у индивидуума, включающий введение индивидууму композиции по п. 1.
25. Способ по п. 24, где заболевание или нарушение представляет собой злокачественную опухоль.
26. Способ по п. 24, где индивидуум является человеком или собакой.
27. Способ по п. 21, где злокачественная опухоль включает солидные опухоли.
RU2019110848A 2016-09-14 2017-09-14 Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств RU2019110848A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394662P 2016-09-14 2016-09-14
US62/394,662 2016-09-14
PCT/US2017/051661 WO2018053201A1 (en) 2016-09-14 2017-09-14 Triblock polypeptide-based nanoparticles for the delivery of hydrophilic drugs

Publications (2)

Publication Number Publication Date
RU2019110848A true RU2019110848A (ru) 2020-10-15
RU2019110848A3 RU2019110848A3 (ru) 2020-12-14

Family

ID=61620141

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019110848A RU2019110848A (ru) 2016-09-14 2017-09-14 Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств

Country Status (5)

Country Link
US (1) US11135301B2 (ru)
EP (1) EP3512868A4 (ru)
CN (1) CN109890833A (ru)
RU (1) RU2019110848A (ru)
WO (1) WO2018053201A1 (ru)

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4976734A (en) 1985-10-31 1990-12-11 Uab Research Foundation Stimulation of chemotaxis by chemotactic peptides
US5336256A (en) 1986-04-17 1994-08-09 Uab Research Foundation Elastomeric polypeptides as vascular prosthetic materials
US5250516A (en) 1986-04-17 1993-10-05 Uab Research Foundation Bioelastomeric materials suitable for the protection of burn areas or the protection of wound repair sites from the occurrence of adhesions
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5362623A (en) 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
CA2279986A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6296831B1 (en) 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US7087244B2 (en) 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
AU752942B2 (en) 1998-04-13 2002-10-03 Massachusetts Institute Of Technology Comb copolymers for regulating cell-surface interactions
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
CA2337129A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
WO2000056774A1 (en) 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
US7163712B2 (en) 2000-03-03 2007-01-16 Duke University Microstamping activated polymer surfaces
US6852834B2 (en) 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US20050255554A1 (en) 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US6660247B1 (en) 2000-06-23 2003-12-09 Battelle Memorial Institute Multiple stimulus reversible hydrogels
EP1911461B1 (en) 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US6528287B2 (en) 2001-02-13 2003-03-04 Nestor D. Tomycz Recombinant human serum transferrins containing peptides for inducing apoptosis in HIV-1 infected cells
EP1423514A2 (en) 2001-09-05 2004-06-02 WHATMAN plc Stable storage of proteins
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US20040101852A1 (en) * 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of CGG triplet repeat binding protein 1 expression
BR0309877A (pt) 2002-05-03 2005-04-26 Millenium Biologix Inc Peptìdeos estimuladores de tecido conectivo
EP1558444B1 (en) 2002-06-24 2016-09-21 Tufts University Silk biomaterials and methods of use thereof
PT1534340E (pt) 2002-09-06 2012-03-13 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US6918284B2 (en) 2003-03-24 2005-07-19 The United States Of America As Represented By The Secretary Of The Navy Interconnected networks of single-walled carbon nanotubes
WO2004096124A2 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2545325C (en) 2003-11-10 2015-01-13 Uab Research Foundation Compositions for reducing bacterial carriage and cns invasion and methods of using same
US7335744B2 (en) 2003-12-23 2008-02-26 The Regents Of The California University Prostate cancer specific internalizing human antibodies
WO2006004778A2 (en) 2004-06-30 2006-01-12 Dentsply International Inc. Implant with a biofunctionalized surface and method for its production
US7884185B2 (en) 2004-07-28 2011-02-08 University Of Delaware Hydrogels and uses thereof
CA2583700A1 (en) 2004-08-11 2006-02-23 Arqule, Inc. Quinone prodrug compositions and methods of use
KR101446503B1 (ko) 2005-06-24 2014-10-06 듀크 유니버시티 열 반응성 생중합체에 기초한 직접 약물 전달 시스템
EP1924654B1 (en) 2005-08-25 2020-05-06 University of Washington Super-low fouling sulfobetaine and carboxybetaine materials and related methods
CA2634034A1 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7709227B2 (en) 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
EP1996236A2 (en) 2006-03-22 2008-12-03 National Institute of Immunology Novel bioconjugates as therapeutic agent and synthesis thereof
WO2007134245A2 (en) 2006-05-12 2007-11-22 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
SI2409988T1 (sl) * 2006-06-13 2015-10-30 Helix Biomedix Inc. Peptidni fragmenti za sprožitev sinteze proteinov zunajcelične matrice
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
US20110039776A1 (en) 2006-09-06 2011-02-17 Ashutosh Chilkoti Fusion peptide therapeutic compositions
US8846624B2 (en) 2006-09-11 2014-09-30 Emory University Modified protein polymers
WO2008055931A1 (de) 2006-11-08 2008-05-15 Basf Se Verwendung von natürlichen, rekombinanten und synthetischen resilinen in der kosmetik
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20090098652A1 (en) 2007-08-17 2009-04-16 Northwestern University Self assembling peptide systems and methods
US8366652B2 (en) 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
ES2319061B1 (es) 2007-09-11 2010-02-10 Biomedal, S.L. Metodo de conservacion de peptidos o proteinas.
US20110207673A1 (en) 2007-11-20 2011-08-25 Ashutosh Chilkoti Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
DE102007057802B3 (de) 2007-11-30 2009-06-10 Geneart Ag Steganographische Einbettung von Informationen in kodierenden Genen
BRPI0820738A2 (pt) 2007-12-14 2015-06-16 Minitube America Inc Separação específica do gênero de células de esperma e embriões
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
KR101026468B1 (ko) 2008-09-10 2011-04-01 한국전자통신연구원 생분자 검출 장치 및 검출 방법
US20110230420A1 (en) 2008-11-17 2011-09-22 Enzon Pharmaceuticals, Inc. Releasable conjugates for nucleic acids delivery systems
WO2010054699A1 (en) 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
MX2011005967A (es) 2008-12-05 2011-06-30 Abraxis Bioscience Llc Peptidos enlazados a sparc y usos de los mismos.
GB0913775D0 (en) * 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
US8497356B2 (en) 2009-02-17 2013-07-30 Duke University Biomolecule polymer conjugates and methods for making the same
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
USPP21973P3 (en) 2009-06-23 2011-06-14 Cellfor Inc. Loblolly pine tree named ‘CF LP1-7696’
EP2287221A1 (en) 2009-07-16 2011-02-23 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Method for the preparation of high molecular weight oligo(alkylene glycol) functionalized polyisocyanopeptides
EP2470200B1 (en) 2009-08-26 2017-03-15 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2011035465A1 (zh) 2009-09-22 2011-03-31 上海市肿瘤研究所 特异性结合蛋白及其使用
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
JP2011220803A (ja) 2010-04-08 2011-11-04 Mitsumi Electric Co Ltd 電界効果トランジスタ素子を具備するバイオセンサ
EP2560684A4 (en) 2010-04-13 2013-11-20 Medimmune Llc FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
EP3305192B1 (en) 2010-05-17 2019-10-09 Sentilus Holdco, LLC Detection devices and related methods of use
EP2418284A1 (en) 2010-08-13 2012-02-15 ERA Biotech, S.A. Protein body-inducing polypeptide sequences
WO2011155565A1 (ja) * 2010-06-10 2011-12-15 国立大学法人九州工業大学 可逆的な性質を示す温度応答性シートとそれを用いた細胞シートの製造方法
US8470967B2 (en) 2010-09-24 2013-06-25 Duke University Phase transition biopolymers and methods of use
JP6189215B2 (ja) 2010-11-01 2017-08-30 ペプチメッド， インコーポレイテッド 細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
US9775803B2 (en) 2011-10-19 2017-10-03 Samsung Electronics Co., Ltd. Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
WO2013065009A1 (en) 2011-11-01 2013-05-10 National Institute Of Immunology A sortase-click reaction suite for synthesis of multivalent dendrimeric protein assembly
KR102109188B1 (ko) 2013-04-01 2020-05-11 삼성전자주식회사 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2014194244A1 (en) 2013-05-30 2014-12-04 Duke University Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates
WO2015051199A2 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
WO2015126480A2 (en) 2013-11-13 2015-08-27 Massachusetts Institute Of Technology Self-assembling underwater adhesives
US10501734B2 (en) 2014-02-06 2019-12-10 Yale University Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids
WO2015130846A2 (en) 2014-02-25 2015-09-03 Duke University Compositions and methods for the site-specific modification of polypeptides
WO2016065273A1 (en) 2014-10-24 2016-04-28 The University Of Chicago Heat-inducible self-assembling protein domains
EP3227348A4 (en) 2014-12-04 2018-07-18 The Trustees of Columbia University in the City of New York Biodegradable thermo-responsive polymers and uses thereof
US9702847B2 (en) 2014-12-30 2017-07-11 Avails Medical, Inc. Systems and methods for detecting a substance in bodily fluid
US9956300B2 (en) 2015-03-18 2018-05-01 Duke Univerity Hydrogels formed from polypeptide micelles and methods of use thereof
WO2016154530A1 (en) 2015-03-26 2016-09-29 Duke University Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
AU2016287499B2 (en) 2015-06-29 2022-08-04 Caris Science, Inc. Therapeutic oligonucleotides
ES2865259T3 (es) 2015-07-20 2021-10-15 Sentilus Holdco LLC Chips, detectores y métodos para fabricarlos y utilizarlos
AU2016301391B2 (en) 2015-08-04 2022-07-28 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US9678037B2 (en) 2015-10-08 2017-06-13 The Regents Of The University Of Michigan Two-dimensional material-based field-effect transistor sensors
US9496239B1 (en) 2015-12-11 2016-11-15 International Business Machines Corporation Nitride-enriched oxide-to-oxide 3D wafer bonding
US20190015520A1 (en) 2015-12-21 2019-01-17 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
AU2017261216B2 (en) 2016-05-06 2023-08-03 Immunoforge Co., Ltd. ELP fusion proteins for controlled and sustained release
AU2018214601A1 (en) 2017-02-02 2019-08-15 Caris Science, Inc. Targeted oligonucleotides
US20210060171A1 (en) 2018-01-26 2021-03-04 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same

Also Published As

Publication number Publication date
EP3512868A1 (en) 2019-07-24
EP3512868A4 (en) 2020-04-15
US20200164082A1 (en) 2020-05-28
WO2018053201A1 (en) 2018-03-22
CN109890833A (zh) 2019-06-14
US11135301B2 (en) 2021-10-05
RU2019110848A3 (ru) 2020-12-14

Similar Documents

Publication Publication Date Title
Youssef et al. Application of some nanoparticles in the field of veterinary medicine
Han et al. Systemic delivery of monoclonal antibodies to the central nervous system for brain tumor therapy
Binnemars-Postma et al. Nanomedicine strategies to target tumor-associated macrophages
US20210220287A1 (en) Peptide/particle delivery systems
ES2749116T3 (es) Composiciones de administración de nanopartículas
ES2539603T3 (es) Agente inductor de inmunidad
CN106793970B (zh) 用于诊断及治疗的纳米载剂及其加工
US20050266090A1 (en) Nanoparticular targeting and therapy
Berlin et al. Noncovalent functionalization of carbon nanovectors with an antibody enables targeted drug delivery
US20140234212A1 (en) Targeted Buccal Delivery of Agents
Kanwar et al. Multimodal iron oxide (Fe3O4)-saturated lactoferrin nanocapsules as nanotheranostics for real-time imaging and breast cancer therapy of claudin-low, triple-negative (ER-/PR-/HER2-)
Yang et al. Gastric cancer combination therapy: synthesis of a hyaluronic acid and cisplatin containing lipid prodrug coloaded with sorafenib in a nanoparticulate system to exhibit enhanced anticancer efficacy and reduced toxicity
Fan et al. Stimuli-free programmable drug release for combination chemo-therapy
Haggag et al. Novel ran-RCC1 inhibitory peptide-loaded nanoparticles have anti-cancer efficacy in vitro and in vivo
Feng et al. Dual-stimuli responsive nanotheranostics for mild hyperthermia enhanced inhibition of Wnt/β-catenin signaling
US11833362B2 (en) Compositions and methods of altering the electric impedance to an alternating electric field
Zhao et al. Recent advances in CXCL12/CXCR4 antagonists and nano-based drug delivery systems for cancer therapy
Diwan et al. Emerging delivery approaches for targeted pulmonary fibrosis treatment
Sen et al. Nanoparticle mediated alteration of EMT dynamics: an approach to modulate cancer therapeutics
RU2019110848A (ru) Наночастицы на основе триблочных полипептидов для доставки гидрофильных лекарственных средств
Xie et al. One-Step photo synthesis of protein-drug nanoassemblies for drug delivery
Chong et al. Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles
CA3008095C (en) A pharmaceutical composition comprising apatite-based matrix and surface modifying agent
US20180021265A1 (en) Compositions and methods for nanoparticle-based drug delivery and imaging
Fan et al. Charge reversal hairpin peptide modified synergy therapeutic nanoplatforms for tumor specific drug shuttling

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210505